Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FTC And Seven States Seek Contempt Against Martin Shkreli For Violating Lifetime Pharma Ban

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

regulatory

◆ Sectors

Pharma & Biotech

◆ Geography

United States

◆ Source

Read at newscord.org →

◆ Verified

Fusion42 · 14 October 2026 · Fusion42 review

The FTC and seven states have filed a contempt motion against Martin Shkreli, alleging that he violated a lifetime ban from the pharmaceutical industry by engaging in drug stock trades and livestreaming himself doing so.

This Wire brief sits within Fusion42's coverage of Pharma & Biotech, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.

◆ ◆ The Wire takeaway

You must prepare for stricter enforcement and reputational risk around lifetime bans in pharma. The door just closed on any pharma-related trading if your compliance is weak.

◆ Coverage

8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026

◆ Topics

Pharma & Biotechftcmartin-shkrelipharma-banregulatory-violationcontempt